Dermatology Efficacy

Results at week 12


FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz is the first and only FDA-approved IL-17A antagonist that includes PASI 100 in the Prescribing Information1

Dermatology efficacy uncover-2 pasi

In UNCOVER-2, 83% of patients taking Taltz achieved sPGA 0,1 vs 2% who received placebo.


ADDITIONAL WEEK 12 RESULTS

In UNCOVER-1 (Taltz n=433; placebo n=431) and UNCOVER-3 (Taltz n=385; placebo n=193), Taltz patients achieved similar results: 89% and 87% of Taltz patients achieved PASI 75 vs 4% and 7% for placebo. Additionally, 71% and 68% of Taltz patients achieved PASI 90 vs 1% and 3% for placebo, and 35% and 38% of Taltz patients achieved PASI 100 vs 0% and 0% for placebo. Also, 82% and 81% of Taltz patients achieved sPGA 0,1 vs 3% and 7% for placebo.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz works early and effectively by week 122

Dermatology efficacy unover-2-12week


In UNCOVER-1, patients receiving Taltz achieved a mean PASI of 1.9 (an 88% improvement from the mean baseline score of 20.1) at week 12. Patients receiving placebo achieved a mean PASI of 18.9 (a 3% improvement from the mean baseline score of 20.3) at week 12.

In UNCOVER-3, patients receiving Taltz achieved a mean PASI of 1.6 (a 92% improvement from the mean baseline score of 20.7) at week 12. Patients receiving placebo achieved a mean PASI of 17.9 (a 14% improvement from the mean baseline score of 21.1) at week 12.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz provided high levels of efficacy compared to placebo at week 12 regardless of previous treatment with a biologic3

Dermatology efficacy uncover-1-2-3 bar


In these trials, 83% of biologic-naive and 80% of biologic-experienced patients receiving Taltz achieved sPGA 0,1 vs 5% and 2%, respectively, for patients receiving placebo.

In the placebo group, biologic-naive (n=535) and biologic-experienced (n=257) patients achieved PASI 75 rates of 5% and 3%, PASI 90 rates of 2% and 0%, and PASI 100 rates of 0% and 0%, respectively.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Efficacy you can see

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 75

Dermatology efficacy before pasi 75

PATIENT AT BASELINE
(PASI SCORE=19.2)

Dermatology efficacy after pasi 75

PATIENT AT WEEK 12
(PASI SCORE=2.8)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE

Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 90

Dermatology efficacy before pasi 90

PATIENT AT BASELINE
(PASI SCORE=32.5)

Dermatology efficacy after pasi 90

PATIENT AT WEEK 12
(PASI SCORE=2.3)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS

Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI 100

Dermatology efficacy before pasi 100

PATIENT AT BASELINE
(PASI SCORE=13)

Dermatology efficacy after pasi 100

PATIENT AT WEEK 12
(PASI SCORE=0)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

See the difference Taltz can make in 12 weeks4-7

Copying, downloading, or other use of patient photos is expressly prohibited.

Psoriasis can impact all areas of the body. The following images are of real adult patients with moderate to severe psoriasis who were treated with Taltz over a 12-week period. Photos at baseline and week 12 can be viewed below. Individual results may vary.

PASI SPGA 0,1

Dermatology efficacy before spga

PATIENT AT BASELINE
(PASI SCORE=4)

Dermatology efficacy after spga

PATIENT AT WEEK 12
(PASI SCORE=1)

Patients received a 160 mg starting dose of Taltz; then 80 mg of Taltz every 2 weeks.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Head-to-head results in 2 disease states8-12

Adult Plaque Psoriasis

IXORA-R
(Results available now)

The primary endpoint was the proportion of patients achieving completely clear skin at week 12.

Click here for data

ClinicalTrials.gov Identifier: NCT03573323

IXORA-S
(Taltz showed superiority in the primary endpoint)

The primary endpoint was the proportion of patients achieving PASI 90 at week 12.

Click here for data

ClinicalTrials.gov Identifier: NCT02561806

UNCOVER-2 and -3
(Taltz showed superiority)

The co-primary outcome measures of these trials were the proportion of patients with sPGA 0, 1 with ≥2-point improvement from baseline, and proportion of patients achieving PASI 75 at week 12.

Click here for data

ClinicalTrials.gov Identifier: NCT01597245, NCT01646177

Adult Psoriatic Arthritis

Taltz has the first head-to-head study to test superiority vs Humira

SPIRIT-H2H
(Taltz showed superiority in the primary endpoint)

The primary outcome measure of this trial was the proportion of patients simultaneously achieving both ACR50 and PASI 100 at week 24.

Click here for data

ClinicalTrials.gov Identifier: NCT03151551

*US - approved Enbrel.

Please refer to the Prescribing Information of each agent for indication, dosage, and administration.

The brands listed are registered trademarks of their respective owners.


SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz established superiority to Tremfya across all efficacy endpoints through week 1213

Tremfya key efficacy endpoints

Secondary efficacy endpoint, PASI 100 at week 24, was type-I error controlled but did not achieve superiority. Noninferiority analysis of PASI 100 at week 24 was prespecified and achieved with a noninferiority margin of -11.4%, but not type-I error controlled (Taltz vs Tremfya treatment difference of -2.3% with 95% CI[-8.4, 3.8]). At week 24, 50% of patients taking Taltz and 52% of patients taking Tremfya achieved PASI 100.

*Primary and secondary endpoints were analyzed according to a prespecified graphical multiplicity adjustment approach.

All patients were ≥18 years of age and had plaque psoriasis with BSA ≥10%, sPGA ≥3, and a PASI score ≥12, and were candidates for phototherapy and/or systemic therapy.

Trial design

Registration Trial Results


SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz was superior to Tremfya in the percentage of patients achieving completely clear skin (PASI 100) at week 1213

PASI 100 results at week 12 were consistent with registration trials

IXORA-R Primary Endpoint

*P<.001 vs Tremfya at weeks 4, 8, and 12.

PASI 100 at week 12 was the primary endpoint.

All patients were ≥18 years of age and had plaque psoriasis with BSA ≥10%, sPGA ≥3, and a PASI score ≥12, and were candidates for phototherapy and/or systemic therapy.

PASI 100 (defined by blinded assessor) is a measure that denotes 100% clearance of skin plaques (a 100% improvement from baseline). Patients achieving PASI 100 have achieved complete resolution of all skin plaques.

Trial design

Registration Trial Results


SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz was superior to Tremfya in providing rapid and visible skin clearance (PASI 75) at week 213

IXORA-R Secondary Endpoint

*P<.001 vs Tremfya at week 2.

PASI 75 response at week 2 was a secondary endpoint.

Prespecified analysis was conducted for PASI 75 at week 12 (Taltz: 87%, Tremfya: 83%). The data were not type-I error-controlled; therefore, results cannot be regarded as statistically significant.

Trial design

Registration Trial Results


SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE

Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz was superior to Stelara in the percentage of patients who achieved PASI 90 and PASI 100 at week 1214

Results at weeks, 12, 24, and 52

Dermatology efficacy ixora h2h

Trial design


SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS

Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Taltz showed superiority in 2 head-to-head trials vs US-approved Enbrel1

Dermatology efficacy uncover-2-3-12w bar

Trial design


SELECT IMPORTANT SAFETY INFORMATION
ADVERSE EVENTS AND DISCONTINUATION RATES FOR TALTZ COMPARED TO US-APPROVED ETANERCEPT

The rate of serious adverse events during the controlled induction period (weeks 0-12) was 0.7% for US-approved etanercept and 2% for Taltz and the rate of discontinuation from adverse events was 0.7% for US-approved etanercept and 2% for Taltz. The incidence of infections was 18% for US-approved etanercept and 26% for Taltz. The rate of serious infections was 0.3% for both US-approved etanercept and Taltz.

FOR BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Taltz was superior to Humira in the percentage of patients who simultaneously achieved both PASI 100 and ACR50 at week 24, with consistency at week 5215.

Primary Endpoint

*P<.05 vs Humira at week 24.

P≤.001 vs Humira at week 52.

Nominal P value: Week 52 measure of ACR50 + PASI 100 was not controlled for type-I error; therefore, no statistical comparisons can be made.

All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, sPGA ≥3 followed the dosing for moderate to severe plaque psoriasis.

Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.

SPIRIT-P1 and -P2: ACR response rates at week 241
In SPIRIT-P1 (biologic-naive) (Taltz 80 mg every 4 weeks n=107; placebo n=106) and SPIRIT-P2 (TNFi-experienced) (Taltz 80 mg every 4 weeks n=122; placebo n=118), 58% and 53% of Taltz patients, respectively, achieved ACR20 vs 30% and 20% for placebo. Additionally, 40% and 35% of patients receiving Taltz achieved ACR50 vs 15% and 5% for placebo.

Primary endpoint=ACR20 response at week 24.
Inadequate responders (<20% improvement in tender and in swollen joint counts) at week 16 were analyzed as nonresponders after week 16 until the primary endpoint.
NRI of intent-to-treat population through week 24.

SPIRIT-P1 and -P2: PASI results at week 12
In SPIRIT-P1 (biologic-naive) (Taltz 80 mg every 4 weeks n=73; placebo n=67), among PsA patients with plaque psoriasis ≥3% BSA, 75% of patients receiving Taltz achieved PASI 75 at week 12 vs 8% of patients who received placebo. 32% of patients receiving Taltz achieved PASI 100 at week 12 vs 2% of patients who received placebo.16 In SPIRIT-P2 (TNFi-experienced) (Taltz 80 mg every 4 weeks n=68; placebo n=67), among PsA patients with plaque psoriasis ≥3% BSA, 57% of patients receiving Taltz achieved PASI 75 at week 12 vs 10% for placebo. Additionally, 19% of patients receiving Taltz achieved PASI 100 at week 12 vs 6% for placebo.17
Among patients with sPGA ≥3 at baseline, in SPIRIT-P1 (biologic-naive) (Taltz 80 mg every 4 weeks n=52; placebo n=41), 75% of patients receiving Taltz achieved sPGA 0,1 at week 12 vs 7% for placebo.13 Additionally, in SPIRIT-P2 (TNFi-experienced) (Taltz 80 mg every 4 weeks n=60; placebo n=55), 63% of patients receiving Taltz achieved sPGA 0,1 vs 4% for placebo.17,18

NRI of intent-to-treat population through week 12.

PASI=Psoriasis Area Severity Index; ACR20/50=American College of Rheumatology 20%/50% response; NRI=nonresponder imputation; BSA=body surface area; sPGA=static Physician’s Global Assessment.

SPIRIT-H2H Trial Design

SPIRIT-P1 and -P2 Registration Trial Design


SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS

Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

FOR BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Taltz demonstrated superiority to Humira in the percentage of patients achieving PASI 100 at week 2419

Primary Endpoint

P=.001 vs Humira at week 24 for PASI 100.
Primary endpoint=simultaneous achievement of ACR50 and PASI 100 at week 24.
All patients had BSA ≥3%; patients with BSA ≥10%, PASI ≥12, sPGA ≥3 followed the dosing regimen indicated for moderate to severe plaque psoriasis.


SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

FOR BIOLOGIC-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Taltz provided comparable improvement in ACR50 to Humira at week 24, NRI15

In SPIRIT-H2H, 51% of patients receiving Taltz (n=283) achieved ACR50 at week 24 vs 47% for Humira (n=283)

Major secondary objective met: demonstrate noninferiority of Taltz vs Humira on ACR50 response at 24 weeks (50.5% vs 46.6%, respectively, 95% CI [-4.3% , 12.1%]) for noninferiority with -12.0% margin.

SPIRIT-H2H Trial Design

SPIRIT-P1 and -P2 Registration Trial Design


SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Challenging body areas


FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Dermatology efficacy tough-to-treat

Subgroup analyses presented for nail, scalp, and palmoplantar psoriasis are post hoc. The UNCOVER studies were not powered for these subgroup analyses, nor were analyses error-controlled. Therefore, treatment differences observed in these subgroups cannot be regarded as statistically significant. Data presented for nail are from the UNCOVER-3 open-label extension period.

Please see below tabs for full data.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Post hoc subgroup analyses of patients with scalp psoriasis20,21*

PSSI 100 response rates at weeks 12 and 60 (induction period and open-label extension)

Dermatology efficacy uncover-3 pasi


ADDITIONAL RESULTS

In UNCOVER-1 (Taltz n=210; placebo n=215) and UNCOVER-2 (Taltz n=144; placebo n=77), 68% and 71% of patients who received Taltz 80 mg every 2 weeks, respectively, achieved PSSI 100 at week 12 vs 3% and 3% for placebo.

Subgroup analyses presented are post hoc. The UNCOVER studies were not powered for these subgroup analyses, nor were analyses error-controlled. Therefore, treatment differences observed in these subgroups cannot be regarded as statistically significant. Baseline severity was not specified in the inclusion criteria.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Post hoc subgroup analyses of patients with nail psoriasis22,23*

NAPSI 0 response rates at weeks 12 and 60 (induction period and open-label extension)

Dermatology efficacy uncover-3 napsi


ADDITIONAL RESULTS

In UNCOVER-1 (Taltz n=172; placebo n=168) and UNCOVER-2 (Taltz n=131; placebo n=72), 7% and 8%, respectively, of patients who received Taltz 80 mg every 2 weeks achieved NAPSI 0 at week 12 vs 0% and 4% for placebo.

Subgroup analyses presented are post hoc. The UNCOVER studies were not powered for these subgroup analyses, nor were analyses error-controlled. Therefore, treatment differences observed in these subgroups cannot be regarded as statistically significant. Baseline severity was not specified in the inclusion criteria.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
PRE-TREATMENT—EVALUATION FOR TUBERCULOSIS

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

More than half of patients achieved sPGA-G 0 by week 1224,25

At week 12, 73% of patients receiving Taltz achieved sPGA-G 0,1 vs 8% of patients receiving placebo.21,25

sPGA-G 0 was a prespecified, exploratory endpoint. It was not controlled for multiplicity; therefore, treatment differences between Taltz and placebo cannot be regarded as statistically significant.

sPGA-G 0,1=primary endpoint.

Dermatology efficacy ixora-q-spga-o-line

NRI of intent-to-treat population through week 12.25

sPGA-G=static Physician’s Global Assessment of Genitalia.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
HYPERSENSITIVITY
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Post hoc subgroup analyses of patients* with palmoplantar psoriasis26,27

PPASI 100 response rate at week 12

Dermatology efficacy uncover-1-2-3-ppasi


ADDITIONAL RESULTS

In UNCOVER-1 (Taltz n=45; placebo n=47), UNCOVER-2 (Taltz n=31; placebo n=18), and UNCOVER-3 (Taltz n=38; placebo n=20), 53%, 52%, and 50%, respectively, of patients who received Taltz 80 mg every 2 weeks achieved PPASI 100 at week 12 vs 9%, 6%, and 10% for placebo.

Subgroup analyses presented are post hoc. The UNCOVER studies were not powered for these subgroup analyses, nor were analyses error-controlled. Therefore, treatment differences observed in these subgroups cannot be regarded as statistically significant. Baseline severity was not specified in the inclusion criteria.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
INFLAMMATORY BOWEL DISEASE

Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbation of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Results at week 60


FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Reassure your patients that consistent results can be maintained with Taltz at week 601

Dermatology efficacy uncover-1-2-60w spga

Of the patients who completed 60 weeks of treatment without relapse (sPGA ≥3) or discontinuation (n=147), 92% maintained clear or almost clear skin (sPGA 0,1) at week 60 based on an observed analysis.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
IMMUNIZATIONS

Prior to initiating Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

Results at week 264


FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Consistent range of response through 5 years, mNRI and observed30

Induction period and open-label extension

Dermatology efficacy uncover-3 5-year

*Nx=observed population.

Analysis presented is post hoc. UNCOVER-3 was not powered for this analysis, nor was the analysis error-controlled. Therefore, treatment differences observed cannot be regarded as statistically significant.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown.

After week 60, dosing could be increased from 80 mg ixekizumab Q4W to 80 mg ixekizumab Q2W if it was determined by the patient and investigator the patient needs additional study drug.

Patients and site personnel were blinded to study treatment until all patients completed week 12 or discontinued. The open-label phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).

In an mNRI analysis of patients receiving Taltz at week 60, 89% of patients achieved PASI 75, 78% of patients achieved PASI 90, and 59% of patients achieved PASI 100. In an mNRI analysis of patients receiving Taltz at weeks 108, 156, 204, and 264, 84%, 82%, 83%, and 79% of patients, respectively, achieved PASI 75; 71%, 69%, 66%, and 67% of patients, respectively, achieved PASI 90; and 50%, 49%, 48%, and 46% of patients, respectively, achieved PASI 100.

mNRI of intent-to-treat population through week 264.

mNRI analysis imputes missing data due to study drug (eg, inadequate response, adverse event, lack of efficacy) as nonresponse; whereas missing data due to other reasons (eg, missed visits, lost to follow-up) are included as a predicted value based on statistical modeling of observed data.

mNRI=modified nonresponder imputation.

Trial design


SELECT IMPORTANT SAFETY INFORMATION
ADVERSE REACTIONS

Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis, and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Rapid clearance by week 12 that was sustained through week 26431

Excludes subjects whose dose escalated to Q2W dosing after week 60 (n=86).

In UNCOVER-1, patients receiving Taltz achieved a mean PASI of 1.9 (an 88% improvement from the mean baseline score of 20.1) at week 12. Patients receiving placebo achieved a mean PASI of 18.9 (a 3% improvement from the mean baseline score of 20.3) at week 12.

In UNCOVER-2, patients receiving Taltz achieved a mean PASI of 1.7 (a 91% improvement from the mean baseline score of 19.4) at week 12. Patients receiving placebo achieved a mean PASI of 19.1 (a 7% improvement from the mean baseline score of 20.6) at week 12.

A subset of patients from UNCOVER-3 who received a 160 mg starting dose of Taltz at week 0, followed by 80 mg every 2 weeks through week 12, followed by 80 mg every 4 weeks, is shown. Patients and site personnel were blinded to study treatment until all patients completed week 12 or discontinued. Data collected weeks 12 to 108 during the long-term extension phase of the study has limitations (eg, no placebo comparison, patients remaining in the extension phase may be those with better results).

Analysis presented is post hoc. UNCOVER-3 was not powered for this analysis, nor was the analysis type-I error-controlled. Therefore, treatment differences observed cannot be regarded as statistically significant.


SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

Trust Taltz to offer


FOR ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Dermatology efficacy taltz header

Trial design


SELECT IMPORTANT SAFETY INFORMATION
INFECTIONS

Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Data on file. Lilly USA, LLC. TAL20160223C. 3. Data on file. Lilly, USA, LLC. TAL20160328C. 4. Data on File. Lilly USA, LLC. TAL20160222D. 5. Data on File. Lilly USA, LLC. TAL20160222A. 6. Data on File. Lilly USA, LLC. TAL20160222E. 7. Data on File. Lilly USA, LLC. TAL20160222B. 8. ClinicalTrials.gov Identifier: NCT03573323. 9. ClinicalTrials.gov Identifier: NCT02561806. 10. ClinicalTrials.gov Identifier: NCT01597245. 11. ClinicalTrials.gov Identifier: NCT01646177. 12. ClinicalTrials.gov Identifier: NCT03151551. 13. Data on file. Lilly USA, LLC. DOF-IX-US-0167. 14. Data on file. Lilly USA, LLC. DOF-IX-US-0006. 15. Data on file. Lilly USA, LLC. DOF-IX-US-0190. 16. Mease PJ, van der Heijde D, Ritchlin CT, et al; on behalf of SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79-87. 17. Nash P, Kirkham B, Okada M, et al; on behalf of SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017;389:2317-2327. Supplementary appendix. 18. Data on file. Lilly USA, LLC. TAL20171127A. 19. Data on file. Lilly USA, LLC. DOF-IX-US-0125. 20. Reich K, Leonardi C, Lebwohl M, et al. Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). J Dermatolog Treat. 2017;28:282-287. 21. Data on file. Lilly USA, LLC. TAL20170829F. 22. Dennehy EB, Zhang L, Amato D, Goldblum O, Rich P. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3. J Drugs Dermatol. 2016;15:958-961. 23. Data on file. Lilly USA, LLC. TAL20170829B. 24. Ryan C, Menter A, Guenther L, et al; on behalf of IXORA-Q Study Group. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase 3b study of patients with moderate-to-severe genital psoriasis [published online ahead of print May 10, 2018]. Br J Dermatol. 2018. doi:10.1111/bjd.16736. 25. Data on file. Lilly USA, LLC. DOF-IX-US-0014. 26. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). J Eur Acad Dermatol Venereol. 2017;31:1686-1692. 27. Data on file. Lilly USA, LLC. TAL20170829D. 28. Data on file. Lilly USA, LLC. TAL20171219A. 29. Data on file. Lilly USA, LLC. DOF-IX-US-0010. 30. Data on file. Lilly USA, LLC. DOF-IX-US-0197. 31. Data on file. Lilly USA, LLC. DOF-IX-US-0232.

Indications and Important Safety Information
Indications

Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 07MAY2020